Skip to content
June 29, 2022

Equity.Guru

Investment information for the new generation

medical mushrooms

Natural Talent Albert Hofmann was a fun guy, pun intended. More importantly, the Swiss chemist is known for being the first person to synthesize, consume, and learn of the psychedelic…
The psychedelics space is one of the hottest investment trips in the public markets today. Embryonic, wide open to possibility and with mounting scientific evidence of psychedelics’ healing properties,…
Aion Therapeutics’ (AION.C) proprietary and patented combinatorial mushroom preparations, Aion F7 and Aion F8, have shown high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and…
Cybin (CYBN.NE) is in a prime position as the push for psychedelic medicine surges across North America and around the world. Scientific evidence supports the life-changing impact of medicinal…
Mydecine (MYCO.C), an upcoming biopharma and life sciences company advocating for the therapeutic use of psychedelic mushrooms, has successfully completed the world’s first legal international export of psilocybin mushrooms….
A cannabis company producing another build-out, another dispensary or pushing forward incrementally isn’t what necessarily passes newsworthy muster. This isn’t 2017 anymore, and it’s generally assumed that most companies…